Drug data · shortage, price, volume
Aprepitant capsules: listed 7 months as a shortage, and the generic benchmark price rose 3% since 2023
The FDA has listed this drug as short in the past. The pharmacy benchmark says the generic capsule now costs $78.69 each, against $130.02 in 2021. Availability and price are different measures, so this page shows both over time.
- The capsule was on the FDA list from July 2015 to January 2016, 7 months, and is not listed now.
- 81% of shortage listings since 2014 lasted as long as this one. The median lasts 21 months.
- A generic 80 mg capsule costs pharmacies $78.69 on the NADAC benchmark in November 2026, 3% above its 2023 level.
- Medicaid paid for 3,046 capsule prescriptions in Q4 2025, 29% more than in Q4 2021.
Not medical advice. This page reports public records about supply and pharmacy cost. Ask a pharmacist or prescriber about your own medication.
Three clocks on one timeline
Each lane uses the same monthly axis, so you can read across: when the FDA listed the capsule, what pharmacies were paying, and how many Medicaid prescriptions were filled.
Swipe the chart sideways to see all 10 years.
How long do shortages last?
Each step is a drop in the share of FDA shortage listings still running. The dot is this drug.
What a pharmacy pays per unit
NADAC is the average price retail pharmacies pay, per capsule.
Which forms are short
| Form | Listed now | Months listed | FDA records (2026-11-05) |
|---|---|---|---|
| capsule | No (last listed January 2016) | 7 | none |
Price by strength
| Strength | Now | 2021 median | First month | Now vs 2021 | History | NDCs |
|---|---|---|---|---|---|---|
| 40 mg | $45.11 | $64.80 | $75.922018-06 | -30% | 9 | |
| 80 mg | $78.69 | n/a | $130.022021-07 | n/a | 16-month gap in NADAC reporting | 13 |
Questions
Is Aprepitant still in shortage?
The capsule is not on the FDA shortage list as of 2026-11-05. It was listed from July 2015 to January 2016. FDA says not to rely on the list for medical care; ask a pharmacist.
Did the shortage raise the pharmacy price?
In the benchmark, yes. The NADAC survey average for a generic 80 mg capsule is $78.69 in November 2026, 3% above its 2023 level. NADAC is a national average of retail pharmacy invoices, so it measures what pharmacies pay on average, not what any one patient was charged.
Did Medicaid fills fall during the shortage?
No. CMS State Drug Utilization Data shows 3,046 Medicaid-paid capsule prescriptions in Q4 2025, 29% more than in Q4 2021 (2,361). Those counts are a floor because CMS suppresses small cells, they cover Medicaid only and move with Medicaid enrollment, and they count prescriptions that were filled, not demand that went unmet. A change in fills is not by itself evidence of a shortage.
What does a pharmacy pay for 30 generic 80 mg capsules?
About $2360.68 on the NADAC benchmark ($78.69 per capsule times 30). That is acquisition cost, not a retail price: it excludes dispensing fees, discounts and rebates.
If you are trying to pay for or find this drug
- Check whether your plan covers it. Tier, prior authorisation and quantity limits for Medicare Part D and commercial plans, 2026 and 2027.
- Look for a free or reduced-cost programme. Manufacturer and nonprofit programmes with their income limits. Confirm current terms with the programme itself.
- Check interactions before any switch. If a pharmacist offers a different strength or product, compare it against everything else you take.
Run a pharmacy, discount card, telehealth or assistance service that helps people pay for medicines? Apply to be evaluated for a page like this one, or hold a disclosed featured slot. Inclusion is earned. A slot is labelled sponsored and never implies a medical endorsement. Building a product on this data? Licence the widget or the data feed.
Cite this page
Figures are calculated from U.S. federal sources (see Data terms below) and rebuilt from dated snapshots. Cite it as:
Embed this chart
Free with attribution: paste this where you want the chart. It sizes itself to its content. A small "Powered by OmniRx" link stays in the widget; white-label licences remove it and add your own branding.
<iframe id="lx-drug-aprepitant" src="https://omnirx.org/embed/drug-aprepitant" width="100%" height="640" style="border:1px solid #e2e8f0;border-radius:10px" title="Aprepitant shortage and price timeline by omnirx.org" loading="lazy"></iframe>
<script>addEventListener('message',function(e){if(e.origin!=='https://omnirx.org')return;var d=e.data||{};if(d.type==='lx-height'&&d.slug==='drug-aprepitant'){var f=document.getElementById('lx-'+d.slug);if(f)f.height=d.height;}});</script>
Sources
- FDA Drug Shortages list and the openFDA drug shortages API, snapshot 2026-11-05.
- Internet Archive captures of the FDA list page, 2014 to 2026, for monthly history (18 months have no usable capture).
- CMS NADAC weekly acquisition cost datasets, 2013 to 2026 (one dataset per year on data.medicaid.gov). Brand and generic follow CMS's own classification for rate setting.
- CMS State Drug Utilization Data, 2017 to 2026.
- openFDA NDC directory for identifiers.
Data terms. Every source above is published by a U.S. federal agency (CMS or FDA). CMS's data site labels its datasets inconsistently: of the 14 NADAC years, 5 carry the "public domain" label and 9 the "U.S. government works" label; of the 14 State Drug Utilization Data years, 6 carry the "public domain" label and 8 the "U.S. government works" label. We record each dataset's label verbatim and cite the source for every figure. Figures on this page are OmniRx calculations from those datasets, not statements by CMS or FDA, and no agency endorses this page.